Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10–45.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Zheng J, Wang S, Xia L, Sun Z, Chan KM, Bernards R, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35.
Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77:1773–96.
Zhan M, Ding Y, Huang S, Liu Y, Xiao J, Yu H, et al. Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase. Nat Commun. 2023;14:3123.
Chen ZL, Xie C, Zeng W, Huang RQ, Yang JE, Liu JY, et al. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases. Signal Transduct Target Ther. 2024;9:181.
Tu S, Zou Y, Yang M, Zhou X, Zheng X, Jiang Y, et al. Ferroptosis in hepatocellular carcinoma: mechanisms and therapeutic implications. Biomed Pharmacother. 2025;182:117769.
Wu Z, Lv G, Xing F, Xiang W, Ma Y, Feng Q, et al. Copper in hepatocellular carcinoma: a double-edged sword with therapeutic potentials. Cancer Lett. 2023;571:216348.
Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25:404–14.
Liu X, Zhang Y, Zhuang L, Olszewski K, Gan B. NADPH debt drives redox bankruptcy: SLC7A11/xCT-mediated cystine uptake as a double-edged sword in cellular redox regulation. Genes Dis. 2021;8:731–45.
Han L, Yang H, Jiang X, Zhou Z, Ge C, Yu K, et al. Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer. Front Immunol. 2024;15:1512203.
Zhou Y, Zhang Y, Zhou Y, Gu Y, Chen Y, Wang J. Bioinformation study of immune microenvironment characteristics of disulfidptosis-related subtypes in ovarian cancer and prognostic model construction. Discov Oncol. 2025;16:18.
Tang M, Dirks K, Kim SY, Qiu Z, Gao Y, Sun D, et al. Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis. Cell Death Differ. 2025;32:598–612.
Wang T, Guo K, Zhang D, Wang H, Yin J, Cui H, et al. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile. Int Immunopharmacol. 2023;120:110368.
Xu K, Dai C, Yang J, Xu J, Xia C, Li J, et al. Disulfidptosis-related lncRNA signatures assess immune microenvironment and drug sensitivity in hepatocellular carcinoma. Comput Biol Med. 2024;169:107930.
Watermann P, Arend C, Dringen R. G6PDi-1 is a potent inhibitor of G6PDH and of pentose phosphate pathway-dependent metabolic processes in cultured primary astrocytes. Neurochem Res. 2023;48:3177–89.
Liang Q, Shen N, Lai B, Xu C, Sun Z, Wang Z, et al. Electrical stimulation degenerated cochlear synapses through oxidative stress in neonatal cochlear explants. Front Neurosci. 2019;13:1073.
Ge Z, Xu M, Ge Y, Huang G, Chen D, Ye X, et al. Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation. Cell Rep. 2023;42:113417.
Li Y, Tang S, Shi X, Lv J, Wu X, Zhang Y, et al. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023;4:101162.
Yan Y, Teng H, Hang Q, Kondiparthi L, Lei G, Horbath A, et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells. Nat Commun. 2023;14:3673.
Reid T, Oronsky B, Caroen S, Quinn M, Williams J, Cabrales P, et al. Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). Front Immunol. 2023;14:1104753.
Oronsky B, Takahashi L, Gordon R, Cabrales P, Caroen S, Reid T. RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist. Front Oncol. 2023;13:1204143.
Guo Y, Bao Q, Hu P, Shi J. Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy. Nat Commun. 2023;14:7306.
Chen M, Song L, Zhou Y, Xu T, Sun T, Liu Z, et al. Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade. Acta Biomater. 2025;194:305–22.
Gong M, Huang Y, Feng H, Lin J, Huang A, Hu J, et al. A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration. J Control Release. 2023;355:68–84.
Chen Y, Mao K, Han D, Ma R, Sun T, Zhang H, et al. Nanomedicine based on chemotherapy-induced immunogenic death combined with immunotherapy to enhance antitumor immunity. Front Pharm. 2024;15:1511423.
Guo W, Jia L, Xie L, Kiang JG, Wang Y, Sun F, et al. Turning anecdotal irradiation-induced anticancer immune responses into reproducible in situ cancer vaccines via disulfiram/copper-mediated enhanced immunogenic cell death of breast cancer cells. Cell Death Dis. 2024;15:298.
Gao X, Huang H, Pan C, Mei Z, Yin S, Zhou L, et al. Disulfiram/copper induces immunogenic cell death and enhances CD47 blockade in hepatocellular carcinoma. Cancers. 2022;14:4715.